Health Management

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Preventive Health & Lifestyle Medicine

Addressing the Challenges of Adolescent Vaccinations: Improving Clinical and Economic Outcomes in Immunizations

The world of immunizations in adolescents has changed dramatically over the past 10 years. From newer vaccines to changing guidelines, the landscape has changed for payers, providers and patients. This webcast will take a close look at those changes on immunizations in adolescents. Attendees will be updated on the latest data and guidelines to help increase rates, costs and patient outcomes.

Addressing the Challenges of Adolescent Vaccinations: Improving Clinical and Economic Outcomes in Immunizations is a webcast that will provide attendees with the latest information on immunizations, costs, burdens and strategies to increase the success of immunizations, and more importantly, patient outcomes and quality of life.
Physician, Nursing and CMCN credits valid to September 30, 2019

Addressing the Challenges of Adult Vaccinations: Improving Clinical and Economic Outcomes in Immunizations

The world of immunizations in adults has changed dramatically over the past 10 years. From newer vaccines to changing guidelines, the landscape has changed for payers, providers and patients. This webcast will take a close look at those changes for adult immunization. Attendees will be updated on the latest data and guidelines to help increase rates, costs and patient outcomes.

Addressing the Challenges of Adult Vaccinations: Improving Clinical and Economic Outcomes in Immunizations is a webcast that will provide attendees with the latest information on immunizations, costs, burdens and strategies to increase the success of immunizations, and more importantly, patient outcomes and quality of life.
Physician, Nursing and CMCN credits valid to September 30, 2019

Behavioral Health

Implementing Shared-Decision Making Strategies: Screening, Diagnosis, and Treatment
of Major Depressive Disorder

Major depression is a debilitating condition that nearly 20% of the general population in the United States will experience at some point in their life. With appropriate treatment, 70-80% of individuals with major depressive disorder (MDD) can achieve a significant reduction in symptoms. More than 80% of patients with depression have a medical comorbidity or complications that can come from MDD to include alcohol or substance abuse, type 2 diabetes, dyslipidemia, obesity, cardiovascular disease, isolation, work and personal conflicts, and an increased chance of suicide. A diagnosis of clinical depression requires the presence of depressed mood, a loss of pleasure and interest, decreased energy, changes in sleep patterns, and feelings of worthlessness, hopelessness, or guilt for a period of at least 2 weeks. The disease leaves the patient with significant distress and impairs their ability to function. Measurement-based assessment tools can help quantify the degree of depression and it is important to utilize a focused severity assessment for hopelessness, suicidal ideation, and psychotic symptoms since these factors independently increase the risk for suicide.

Treatment may be multi-faceted, combining medication with psychotherapy however treatment may change several times as different medications affect people in different ways. Treatments for MDD range from psychotherapy, antidepressants, electroconvulsive treatment (ECT), and other somatic therapies. Antidepressant treatments include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), atypical and tricyclic antidepressants, monoamine oxidase inhibitors and other medications. Combination can affect multiple monoamine targets which can produce greater efficacy. While there are many options available, the need to personalize a treatment plan for each individual patient is important as the ultimate goal of care is to move patients suffering from MDD to remission, then recovery, and to avoid a relapse.

Physician, Nursing and CMCN credits valid to August 15, 2019

Recent Advances in the Treatment of Schizophrenia: Increasing Adherence to Optimize Outcomes

Schizophrenia is a mental illness that takes away a person’s ability to think clearly, manage emotions, make decisions and socialize with others. It is a complex, long-term medical illness, affecting about 2.4 million American adults. Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 30s. The difficulty of diagnosing this illness is compounded by the fact that many people who are diagnosed do not believe they have it. While there is no single physical or lab test that can diagnosis schizophrenia, a health care provider who evaluates the symptoms and the course of a person’s illness over six months can help ensure a correct diagnosis. The health care provider must rule out other factors such as brain tumors, possible medical conditions and other psychiatric diagnoses, such as bipolar disorder. As with most diseases, the earlier the disease is diagnosed, the chances of managing the disease will be significantly higher.

There is no cure for schizophrenia thus the goal of treatment is to reduce the symptoms and to decrease the chances of a relapse. Antipsychotic medications are proven effective in treating acute psychosis and reducing the risk of future psychotic episodes. First-generation and second-generation antipsychotics pose different efficacy, risks, and cost while emerging therapies may overcome the side effects such as weight gain, depression, suicide, restlessness, stiffness, tremors, and muscle spasms. Non-pharmacologic forms of therapy, such as psychosocial interventions and electroconvulsive therapy, are also available for patients who do not respond to drug therapy.
Physician, Nursing and CMCN credits valid to January 31, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Chronic Illness

Improving Patient Adherence and Quality of Life in Psoriasis: Strategies for Managing Treatment Related Adverse Events Associated with New Biologics

During this three part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.
Physician, Nursing and CMCN credits valid to February, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

AutoImmune

Evolving Treatment Paradigms in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Managed Care Considerations on Immunoglobulin Replacement Therapy

Effective and timely treatment of primary immunodeficiency diseases can greatly improve the quality of life and outcomes in CIDP patients. With the advancement and complexity of different treatment options, including immunoglobulin replacement therapies that have become available recently in different administration methods, it is critical that medical directors, payers, practicing physicians, nurse case managers and other HCPs are educated on the role of immunoglobulin replacement therapy and understand all of the safety and efficacy data to make appropriate formulary and clinical decisions. Recent surveys, research and evaluations from our activities have shown that these healthcare professionals need updates on these novel options, and how they can integrate them into the treatment paradigm and optimize costs. This webcast activity will feature strategies to overcome challenges in the optimal treatment of CIPD, updates on immunoglobulin replacement therapies, and practical managed care approaches to provide cost-effective solutions to improve both clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to February 1, 2020

Best Practices in the Treatment and Management of Systemic Lupus Erythematosus (SLE): Addressing Disease Activity and Flares for Improved Clinical and Economic Outcomes

Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to September 30, 2019

Addressing Disease Activity and Flares for an Individualized Approach to Managing Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to September 30, 2019

A Managed Care Evaluation of Current Therapies and Updates in the Management of Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to September 30, 2019

Improving Patient Adherence and Quality of Life in SLE: Strategies for Improving Administration and Managing Adverse Events

Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Diagnosis can be difficult and is based on a combination of symptoms and laboratory tests. Systemic lupus erythematosus (SLE) is the most common form of lupus and affects approximately 70 percent of an estimated 5 million people with lupus worldwide. Approximately 170,000-200,000 Americans live with SLE. Fortunately, over the past decade several new agents have become available, or are on the horizon. These options have proven to reduce lupus disease activity, and developments have been made to make administration easier for improving patient adherence and quality of life. With these recent developments, it is imperative to provide medical directors, primary care physicians, rheumatologists, and others on the interprofessional management team with updated guidelines and strategies for optimizing patient adherence and quality of life, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to September 30, 2019

Optimizing Clinical and Economic Outcomes in the Management of Primary Immunodeficiency Diseases: Taking a Closer Look at the Role of Immunoglobulin Replacement Therapy

Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. Some affect a single part of the immune system; others may affect one or more components of the system. And while the diseases may differ, they all share one common feature: each results from a defect in one of the functions of the body’s normal immune system. Fortunately for patients with primary immunodeficiency disorders, the treatment paradigm has exploded in the past 10 years, giving medical directors and clinicians many more options in managing the PIDD patient population. The primary treatment for these patients with antibody deficiencies is lifetime administration of immunoglobulin replacement therapy; a therapeutic substance derived from human blood plasma and made up of immunoglobulin. These therapies have shown improved efficacy and safety for patients with PIDDs. Since Ig only replaces the missing end product but does not correct the patient’s defect in antibody production, Ig replacement is usually necessary for the patient’s lifetime. Although approximately 150,000 patients are likely to benefit from Ig replacement, only an estimated 35,000 to 55,000 receive ongoing therapy. A lack of awareness and depth of understanding contribute to this underserved population of individuals with PI thus it’s imperative healthcare professionals who manage PIDD patient populations have a solid understanding of differing options to optimize both costs and patient outcomes in their therapeutic application.
Physician, Nursing and CMCN credits valid to August 1, 2019

Personalized Treatment Strategies for IBD: Improving Patient Care and Outcomes

Inflammatory bowel disease (IBD) is a chronic, systemic autoimmune illness often strikes patients at a young age and the diagnosis of IBD is most commonly based on imaging, a critical role in the initial diagnosis, to assess the portions of the small bowel that is inaccessible to optical endoscopic visualization. This may also include a combination of endoscopy and histopathology. Immediate goals are to control the symptoms, achieve remission, and to help improve a patient’s quality of life, while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, endoscopic remission, prevention or cure of complications, restoration, and maintenance of proper nutrition. The first pharmacological option are aminosalicylates, which are useful for treating flares and maintaining remission. Antibiotics may also be used to treat bacterial infections that may result from abscesses or fistulas. Corticosteroids are rapid-acting anti-inflammatory agents and are indicated for acute flares of disease only and have no role in the maintenance of remission. Immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system. Finally, the use of biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract, are usually prescribed to those living with moderate to severe cases of IBD who haven’t responded to other types of treatment. Now that there is a better understanding of the pathogenesis of IBD, the development of new therapies targeting the inflammatory pathways is considered a high priority.
Physician, Nursing and CMCN credits valid to August 15, 2019

Novel Treatment Advances and Approaches in Rheumatoid Arthritis: Personalizing Therapy for Improved Clinical and Economic Outcomes

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, treatment is to control the pain, during flair ups especially, and to prevent joint damage. Rheumatoid arthritis varies greatly from patient to patient, and with each patient it varies over time. There may be flare-ups, where the pain and inflammation are much worse, or times of “remission” where the pain and inflammation disappear or almost disappear. In addition, many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors, and several more have just completed late stage clinical trials and are currently undergoing regulatory review. These new options have shown improved efficacy and safety in RA.
Physician, Nursing and CMCN credits valid to August 10, 2019

Implementing Newer Biologic Therapies to Improve Economic and Clinical Outcomes in Patients with Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by periods of acute disease flare that may include painful burning sensations and persistent itching. AD occurs more frequently in adulthood, is often accompanied by co-morbidities such as rhinitis and asthma, and can severely affect quality of life. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States with an estimated annual direct and indirect cost of approximately $5 billion dollars. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term but have had troubles with long term efficacy. Thankfully advances in the understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, such as JAK and PDE4 inhibitors, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2019

Exciting Perspectives on Treating Psoriatic Arthritis: Exploring Personalized Treatment Strategies

Psoriatic arthritis (PsA) is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations that often lead to extreme pain and joint damage that may affect a patient’s quality of life, physical function, and ability to work. This potentially disfiguring condition remains underdiagnosed and symptoms include fatigue, joint inflammation, and potentially progressive, irreversible joint damage. Diagnosing PsA can be very complex and may be easier to confirm if psoriasis coexists with symptoms of arthritis, however symptoms of PsA appear before symptoms of psoriasis. A careful medical history, physical examination, blood tests, magnetic resonance imaging (MRI), and x-rays of the involved joints along with a dermatologic evaluation may be used to diagnose PsA. The goals of treatment for PsA include early diagnosis, with early aggressive treatment aimed at limiting joint damage and clearing psoriasis. The treatment recommendations for PsA include the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying antirheumatic drugs (DMARDs). Fortunately, novel biologic treatments have been developed and proven to stop joint damage, pain, and swelling in moderate to severe disease. These treatments include adalimumab, etanercept, golimumab, certolizumab, and infliximab. Other biologics have been produced that help block proteins IL-12, IL-23, and IL-17. These biologics reduce inflammation, are given by a subcutaneous injection, and are producing results that treat the skin as well as arthritis.
Physician, Nursing and CMCN credits valid to July 31, 2019

Optimizing Treatment Strategies in the Management of Rheumatoid Arthritis: Novel Therapies for Improved Patient Outcomes

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications and to rule out other possible causes for the symptoms. There is no cure for RA, treatment is to control the pain, during flair ups especially, and to prevent joint damage. Rheumatoid arthritis varies greatly from patient to patient, and with each patient it varies over time. Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare professionals. An understanding of the pathogenesis of RA and the role of different treatment approaches, including current and emerging therapies, will assist healthcare providers in determining the best course of therapeutic management for optimal long-term patient outcomes. Fortunately, new treatments, to include non-biologic DMARDS, have shown improved efficacy and safety and should be implemented into the treatment paradigm to ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to April 30, 2019

New Horizons in the Treatment and Management of Moderate to Severe Psoriasis: Tailoring Treatments to Achieve Improved Patient Outcomes and Quality of Life

During this three-part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.
This multi-part program on new horizons in the treatment and management of psoriasis will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.
Physician, Nursing and CMCN credits valid to February 28, 2019

A Deeper Look into IL-17 and IL-23 Inhibitors in the Management of Moderate to Severe Psoriasis: Exploring New Pathways to Clearer Skin

During this three part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.
Physician, Nursing and CMCN credits valid to February, 2019

Comparative Effectiveness and Coordinated Care in Moderate to Severe Psoriasis: What Does Managed Care Need to Know about Novel Biologic Therapies?

During this three-part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.
Physician, Nursing and CMCN credits valid to February, 2019

Personalized Treatment Strategies in the Management of Psoriasis

Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million, or just over 2%, of the population in the United States. The main disease activity leading to psoriasis occurs within the top 5 layers of the epidermis and most commonly appears on the skin of the scalp, elbow, knees, and lumbosacral areas of the body. Psoriasis is a periodic flare-up of itchy, sharply defined red patches covered by a silvery, flaky surface. The disease is complex to manage and a patient-centered treatment approach is encouraged as the goal is to reduce disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbidities. Unfortunately, the disease is under diagnosed and expensive to treat thus early diagnosis and treatment are likely to reduce the economic burden. Choosing the most effective therapy depends on factors such as the location, severity and type of psoriasis. Topical agents remain the standard treatment in the first line setting, however patient adherence is quite poor. Systemic medication is prescribed orally or by injection while photo or laser therapy are also effective yet expensive and require frequent doctor visits; adding to the disease burden. Fortunately, novel oral medications which target small molecules and biologics have shown efficacy in clinical trials. Recent research indicates that both IL-23 and IL-17 pathways play important, and perhaps integral roles in the development of psoriatic plaques.
Physician, Nursing and CMCN credits valid to January 31, 2019

New Targets in the Therapeutic Landscape for Moderate-to-Severe Atopic Dermatitis (AD): What Does Managed Care Need to Know?

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term, but have had troubles with long term efficacy. Thankfully advances in the understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.
Physician, Nursing and CMCN credits valid to January 31, 2019

Understanding the Ever-Changing World of Biosimilars

A biosimilar is a biologic drug that is developed to be highly similar, but not identical, to an existing biologic. They are a large molecule that is typically derived from living cells and can be used in the prevention, diagnosis, and/or treatment of the disease. Biologic agents have revolutionized the treatment of many diseases, including several cancers, inflammatory bowel disease (IBD), rheumatoid arthritis, and many more. Now, with patents continuing to expire on these first biologics, biosimilar products are becoming available. These agents are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers. The FDA looks at biosimilars as a biological product that is similar to a U.S. licensed biological product not including minor differences in clinically inactive components, as well as having no clinically meaningful differences between the biological product and

 

the reference product in terms of the safety, efficacy and potency of the product. The development of new biologics may be a big step in effectively treating diseases for which there are currently no cures. Approvals of more biosimilars focused on oncology products, as well as biosimilars for anti-TNF biologics, are anticipated in the later stages of 2017.
Physician, Nursing and CMCN credits valid to January 31, 2019

New Developments in the Diagnosis and Treatment of Psoriatic Arthritis

Psoriatic arthritis is a debilitating, progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations that affect men and women equally. Patients often experience extreme pain and joint damage which affect their quality of life, physical function, and ability to work. Approximately 30% to 40% of people with psoriasis will also develop psoriatic arthritis, a painful and potentially disfiguring condition that remains underdiagnosed. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage. Diagnosis may be easier to confirm if psoriasis coexists with symptoms of arthritis. However, in as many as 15% of cases, symptoms of psoriatic arthritis appear before symptoms of psoriasis. A careful medical history, physical examination, blood tests, magnetic resonance imaging (MRI), and x-rays of the involved joints along with a dermatologic evaluation may be used to diagnose psoriatic arthritis. In addition to early diagnosis, the goal of treatment for psoriatic arthritis is to properly manage the disease by obtaining remission; which includes prompt, aggressive treatment aimed at limiting joint damage and clearing skin psoriasis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and traditional disease-modifying antirheumatic drugs (DMARDs) are used to reduce inflammation caused by arthritis with the intent of reducing pain, swelling and stiffness. However, many of these medications suppress the immune system and lead to a potential increase risk of infections. Thankfully novel biologic treatments have been developed and have been proven to stop joint damage as well as pain and swelling in moderate to severe psoriatic arthritis.
Physician, Nursing and CMCN credits valid to January 31, 2019

A 4-Part Series:  New Horizons in the Treatment and Management of Atopic Dermatitis (AD): How Novel Therapies are Changing the Treatment Paradigm

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. Current treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with severe eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently undergone late stage clinical trials that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on the latest clinical data on these evolving options, how clinicians can potentially integrate them into the treatment paradigm, options for patients who have received prior therapies, and information on the mechanisms of action of these agents.

Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin. These treatments have shown the ability to managed the disease in the short term, but have had troubles with long term efficacy. A recent update to the American Academy of Dermatology guidelines of care for the management of adult and pediatric patients recommends a proactive approach for long-term disease management versus episodic management of flares with an emphasis on clinical assessment of disease severity. Several treatments, including novel monoclonal antibodies, have shown the ability in late stage clinical trials to block various proteins that mediate inflammation and immune responses, potentially arresting development and progression of the disease at various pathogenic steps. These new options have shown improved efficacy and safety in atopic dermatitis, and medical directors, practicing physicians, nurses and other healthcare professionals must be educated on these options and how they might affect the current treatment paradigm.

This multi-part program on new horizons and novel therapies in atopic dermatitis will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Clinicians need to be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients, especially in the area of inadequately controlled moderate-to-severe atopic dermatitis patients.
Physician, Nursing and CMCN credits apply.  Each session has its own specific valid dates.

What’s on the Horizon in Atopic Dermatitis (AD): A Closer Look at Integrating Emerging Targeted Therapies into the Treatment Paradigm

Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address the novel and emerging therapies available for AD.
Physician, Nursing and CMCN credits valid to April 30, 2019

Managing Inadequate Response in Moderate-to-Severe AD: Strategies for Patients whose Disease is Not Controlled by Standard Therapy

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address how to manage patients not controlled by standard therapy, the challenges, tailored treatment plans and continued patient assessments.
Physician, Nursing and CMCN credits valid to April 30, 2019

Recent Advances in Understanding the Pathogenesis of Atopic Dermatitis

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address the role of emerging therapies and their pathophysiologic mechanisms that block IL-4/IL-13 pathways.
Physician, Nursing and CMCN credits valid to April 30, 2019

New Horizons in the Treatment and Management of Atopic Dermatitis (AD): What Managed Care Needs to know about Novel Therapies in the Evolving Management of Atopic Dermatitis

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will provide attendees with perspectives and strategies used to manage an AD population by managed care organizations.

Physician, Nursing and CMCN credits valid to April 30, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Cardiovascular

Practical Strategies for Improving Diagnosis and Treatment of PAH

Pulmonary Arterial Hypertension (PAH) is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. PAH is a progressive vascular disorder where continuous, exceedingly high blood pressure exists in the pulmonary artery – the blood vessel that carries blood from the right ventricle of the heart into the small arteries in the lungs. As arteries narrow, they are more resistant to blood flow, which can cause stiffening or even the formation of tiny blood clots, sometimes causing blockages as the heart works harder to pump blood into the lungs. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Additionally, PAH often leads to several co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing the disease and its associated costs.
Physician, Nursing and CMCN credits valid to August 31, 2019

What Managed Care Needs to Know in the Evolving Treatment of Heart Failure: Novel Therapies for Improved Clinical and Economic Outcomes

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is responsible for over one million hospitalizations in the U.S. per year which attributes to an estimated $31 billion in costs. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of several new classes of medications that have shown improved clinical outcomes in patients with HF. Although these new and emerging therapeutic options have shown to lower mortality their application in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high. In fact, HF is the leading cause of hospitalization among adults over the age of 65 in the U.S. Thus, it is critical that physicians and healthcare providers implement individualized treatment strategies, promote shared decision-making with patients and, ultimately, enhance patient quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2020

A Deeper Look into the Newest Therapies in the Management of Heart Failure: Individualizing Therapy for Improved Clinical and Economic Outcomes

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is responsible for over one million hospitalizations in the U.S. per year which attributes to an estimated $31 billion in costs. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of several new classes of medications that have shown improved clinical outcomes in patients with HF. Although these new and emerging therapeutic options have shown to lower mortality their application in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high. In fact, HF is the leading cause of hospitalization among adults over the age of 65 in the U.S. Thus, it is critical that physicians and healthcare providers implement individualized treatment strategies, promote shared decision-making with patients and, ultimately, enhance patient quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2020

Comparative Effectiveness and Coordinated Care in Heart Failure: What Does Managed Care Need to Know about Novel Therapies?

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is responsible for over one million hospitalizations in the U.S. per year which attributes to an estimated $31 billion in costs. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of several new classes of medications that have shown improved clinical outcomes in patients with HF. Although these new and emerging therapeutic options have shown to lower mortality their application in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high. In fact, HF is the leading cause of hospitalization among adults over the age of 65 in the U.S. Thus, it is critical that physicians and healthcare providers implement individualized treatment strategies, promote shared decision-making with patients and, ultimately, enhance patient quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2020

Improving Patient Adherence, Quality of Life and Transitions in Care in Heart Failure Management

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is responsible for over one million hospitalizations in the U.S. per year which attributes to an estimated $31 billion in costs. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of several new classes of medications that have shown improved clinical outcomes in patients with HF. Although these new and emerging therapeutic options have shown to lower mortality their application in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high. In fact, HF is the leading cause of hospitalization among adults over the age of 65 in the U.S. Thus, it is critical that physicians and healthcare providers implement individualized treatment strategies, promote shared decision-making with patients and, ultimately, enhance patient quality of life.
Physician, Nursing and CMCN credits valid to August 1, 2020

The Role of PCSK9 Inhibitors in Lowering LDL-C and Reducing Cardiovascular Risk in Patients with Dyslipidemia: What Managed Care Needs to Know

LDL-C is a major factor in the development of cardiovascular disease (CVD) which effects over 73 million adults in the United States. It is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Recent studies have begun debates among healthcare professionals about how best to measure LDL in order to identify patients at high risk for CVD and individualize therapy for them. Another area of intense interest is whether directing treatment to additional lipid targets will reduce the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins which inhibit the liver’s production of LDL cholesterol in the first place, and to which some patients don’t respond well. Recent data has shown that these PCSK9 agents cut levels of LDL cholesterol by close to 70 percent, more than statins alone.
Physician, Nursing and CMCN credits valid to August 1, 2020

A Late-Breaking Update on PCSK9 Inhibitors and Recent Cardiovascular Outcomes Data: Individualizing Therapy for Improved Clinical and Economic Outcomes

LDL-C is a major factor in the development of cardiovascular disease (CVD) which effects over 73 million adults in the United States. It is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Recent studies have begun debates among healthcare professionals about how best to measure LDL in order to identify patients at high risk for CVD and individualize therapy for them. Another area of intense interest is whether directing treatment to additional lipid targets will reduce the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins which inhibit the liver’s production of LDL cholesterol in the first place, and to which some patients don’t respond well. Recent data has shown that these PCSK9 agents cut levels of LDL cholesterol by close to 70 percent, more than statins alone.
Physician, Nursing and CMCN credits valid to August 1, 2020

A Managed Care Evaluation of PCSK9 Inhibitors in the Management of Dyslipidemia

LDL-C is a major factor in the development of cardiovascular disease (CVD) which effects over 73 million adults in the United States. It is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Recent studies have begun debates among healthcare professionals about how best to measure LDL in order to identify patients at high risk for CVD and individualize therapy for them. Another area of intense interest is whether directing treatment to additional lipid targets will reduce the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins which inhibit the liver’s production of LDL cholesterol in the first place, and to which some patients don’t respond well. Recent data has shown that these PCSK9 agents cut levels of LDL cholesterol by close to 70 percent, more than statins alone.
Physician, Nursing and CMCN credits valid to August 1, 2020

Breaking Down the Barriers to PCSK9 Inhibitor Use in Clinically Appropriate Patients: Bringing the Team Together to Improve Patient Outcomes

LDL-C is a major factor in the development of cardiovascular disease (CVD) which effects over 73 million adults in the United States. It is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Recent studies have begun debates among healthcare professionals about how best to measure LDL in order to identify patients at high risk for CVD and individualize therapy for them. Another area of intense interest is whether directing treatment to additional lipid targets will reduce the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins which inhibit the liver’s production of LDL cholesterol in the first place, and to which some patients don’t respond well. Recent data has shown that these PCSK9 agents cut levels of LDL cholesterol by close to 70 percent, more than statins alone.
Physician, Nursing and CMCN credits valid to August 1, 2020

Improving Clinical Outcomes in the Treatment and Management of PAH

Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder and though relatively rare, PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure – the most common cause of death for PAH patients. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs. Thankfully advancements in diagnostic criteria, guidelines, classifications and emerging treatments continue to be updated to find the best treatment for the severity and individual nature of the disease in each patient. There are several treatments for PAH depending on the severity and the patient’s profile. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019

New Therapeutic Options in the Management of Chronic Heart Failure:Optimized Strategies for Improved Patient Outcomes

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. Fortunately for patients with chronic HF, new and emerging therapeutic options have shown the promise for improving outcomes for these patients. Although multiple therapies have shown to lower mortality in patients with HF, their applications in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high.
Physician, Nursing and CMCN credits valid to January 31, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Diabetes

What’s New in the Evolving Management of Type 2 Diabetes: Individualizing Therapy with Novel Treatment Options

The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States have diabetes and that 1 in 3 Americans born in 2017 will develop diabetes at some point of their life. Approximately 90-95% of adults have type 2 Diabetes Mellitus (T2DM) and the Centers for Disease Control (CDC) estimates that uncontrolled type T2DM doubles a person’s risk for death, and on average a loss of 10-15 years of life. The management of type T2DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. The price tag associated with treatment of type T2DM increases with disease severity, as more dollars are spent managing the significant comorbidities associated with advanced disease. Moreover, it is estimated that diabetes patients, on average, have medical expenditures that are approximately 2.3 times higher relative to the absence of diabetes. Fortunately, recent advances in treatments have given healthcare professionals the ability to shrink the clinical practice gap and implement therapeutic strategies to effectively treat this disease. Incorporating an individualized regimen for patients, to include education, lifestyle change, mono and combination therapy of GLP-1 agonists, insulins and SGLT-2 inhibitors, will help overcome the barriers associated with T2DM.
Physician, Nursing and CMCN credits valid to January 31, 2019

Individualizing Treatment in T2D Management: Novel Therapies for Improved Patient Outcomes

While the prevalence of diabetes continues to rise, a new generation of treatments has become available in the past few years. Despite new regimens, barriers to care, such as patient adherence and economic burden, still exist. It has been estimated that people diagnosed with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than what expenditures would be in the absence of diabetes. The price tag associated with treatment of type 2 DM increases with disease severity, as more and more dollars are spent managing the significant comorbidities associated with advanced type 2 DM. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments for Type 2 Diabetes have given healthcare professionals the ability to individualize care. New data and guideline updates offer best practices in regard to the role of mono and combination therapies. Treatments have become available that allow the individualization of T2DM management. There have been many questions in member surveys and past program evaluations about the best practices in regard to the role of combination therapies comprised of SGLT-2 inhibitors in the management of type 2 diabetes, and new data and guidelines updates showing the benefits and risks of these new therapies.
Physician, Nursing and CMCN credits valid to August 31, 2018

A 4-Part Series: New Horizons in the Treatment and Management of Type 2 Diabetes; Individualizing Therapy with Novel Options for Improved Patient Outcomes

Description:  The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap.

Upon completion of these activities, it is anticipated that learners will be better able to identify the potential consequences of inadequate control of T2DM, apply objective disease-activity measures to determine whether patients are meeting treat-to-target goals, develop management plans for treating to target and advancing of novel therapies to achieve continued control of T2DM, and evaluate the role of the medical director, pharmacy director and nurse case manager in improving outcomes and costs in a population of T2DM patients.
Physician, Nursing and CMCN credits apply. Each session has its own specific valid dates.

Improving Glycemic Control and Cardiovascular Risk with Novel Therapies

The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019

GLP-1 Agonists, Insulin and SGLT-2 Inhibitors in the Changing Treatment Paradigm: What are the Benefits, Risks and Outcomes in Patients with Type 2 Diabetes?

The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019

What Managed Care Needs to Know About Novel Therapies in the Evolving Management of Type 2 Diabetes

The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019

Hemophilia

Redefining Clinical Outcomes in Hemophilia: The Impact of Personalized Treatment Strategies

Hemophilia is an inherited disorder caused by a defect in one of the X chromosomes resulting in excessive bleeding and easy bruising. While females are typically carriers of the genetic defect, the majority of cases are seen in males and it’s believed that around 1 in 5,000 males are born with it every year. Bleeding can be external or internal and bleeding into the joints is especially a problem as it can cause long term damage if not treated quickly. Bleeding in the brain is an even more serious problem for those with severe hemophilia, since it can be caused by a simple head bump. Hemophilia A is more common than B and each type require different treatments. Hemophilia is diagnosed through blood tests to determine the severity of the disease and discover which clotting factor is low or missing. Replacement therapy remains the mainstay of treatment which contain concentrates of clotting factor which is infused and can be synthetic or made with human blood. Early treatment and prophylactic therapy is critical to effectively managing the disease and improving patient outcomes by preventing joint damage. Demand therapy is done on an as needed basis. Patient education is also critical as infusions can be taught to patients and done at home, alleviating unnecessary doctor appointments and lowering the cost of treatment. Replacement therapy can be taught to a capable person, and infusions can be done at home, making for quicker treatment with less stress, less visits to the doctor, and less cost.
Physician, Nursing and CMCN credits valid to August 1, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Infectious Disease

Novel Treatment Advances in the Management of Serious Gram-Negative Bacterial Infections: Expert Strategies for Improved Patient Outcomes

The program will be on newer therapies in Gram-Negative Bacterial Infections, with a close look at options such as such as ceftolozane/tazobactam. The program will discuss how these newer option fits into the established paradigm and what healthcare professionals need to know about this option. The webcast will focus on how to manage gram-negative infections.
Physician, Nursing and CMCN credits valid to November 26, 2019

Novel Treatment Advances and Approaches in the Prevention and Management of Cytomegalovirus (CMV) Infection

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.
Physician, Nursing and CMCN credits valid to September 30, 2019

Informed Decision-Making in the Management of HIV/AIDS: Expert Strategies for Individualized Treatment

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 persons in the United States aged 13 years and older are living with HIV infection. Additionally, an estimated 6,955 people died from HIV and AIDS in 2017. HIV treatment focuses on controlling the disease and living longer, healthier lives. One of the biggest challenges for clinicians is individualizing the care of HIV-positive patients and understanding when certain ART therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ART must be tailored to the individual patient and his or her abilities and diverse needs. Fortunately, new treatments have become available over the past couple of years offering physicians additional options to address the unmet needs of these HIV patients, including combination regimens.
Physician, Nursing and CMCN credits valid to August 10, 2019

New Options in the Treatment of Hepatitis C (HCV): Economic and Clinical Considerations for Improved Patient Outcomes

Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Approximately 75% to 85% of HCV-infected persons will progress to chronic HCV infection and are at risk for the development of extrahepatic manifestations, compensated and decompensated cirrhosis, and hepatocellular carcinoma. Approximately 3.5 million persons in the United States are chronically infected today. HCV-associated disease represents the leading indication in the United States for liver transplantation and the leading cause of hepatocellular cancer. The rapid evolution of therapeutic choices in HCV presents opportunities and substantial challenges to healthcare professionals. In light of evidence for the superior efficacy and adverse effect profiles of new and emerging therapies, health care professionals must select patients for treatment based on a thorough understanding of the clinical, economic, and societal ramifications of their decisions. This activity will help health care professionals implement practice changes and policies to improve patient outcomes in a cost-effective manner.
Physician, Nursing and CMCN credits valid to June 30, 2019

A Difficile Challenge: The Impact of New Therapies on Clinical Outcomes and Economics in C. Difficile Infection

Clostridium difficile, a Gram-positive bacteria that causes diarrhea, abdominal bloating, and colitis, is associated with significant morbidity and mortality. Up to 25% of patients with an initial episode of C. difficile infection (CDI) experience disease recurrence. Recurrent CDI is particularly challenging to manage. Although a number of therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. This webinar will provide attendees with up-to-date knowledge of evidence-based treatment and management strategies of initial and recurrent CDI to improve clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to May 31, 2019

Individualized Treatment in the Management of HIV/Aids: Advanced Strategies for Improved Patient Outcomes

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare professionals. HIV treatment focuses on controlling the disease and living longer, healthier lives. Antiretroviral therapy (ART) is the use of HIV medicines to treat HIV infection. ART has evolved considerably over the past three decades. With many antiretroviral drugs, combinations, and classes available, health care providers have multiple choices regarding ART. While these choices provide clinicians with many useful options, they also lead to challenges. One of the biggest challenges for clinicians is individualizing the care of HIV-positive patients and understanding when certain ART therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ART must be tailored to the individual patient and his or her abilities and diverse needs. Fortunately, new treatments have become available over the past couple of years offering physicians additional options to address the unmet needs of these HIV patients.
Physician, Nursing and CMCN credits valid to April 30, 2019

Improving Patient Outcomes with Individualized Therapy in the Management of HIV/AIDS

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Fortunately for patients with HIV, several new therapies have recently become available for clinicians. Antiretroviral therapy (ART) has evolved considerably over the past three decades with many antiretroviral (ARV) drugs, combinations, and classes available. Cobicistat-boosted protease inhibitors (PI) are also evolving and one of the biggest challenges for clinicians is individualizing care and understanding when certain ARV therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ARV therapy must be tailored to the individual patient and his or her abilities and diverse needs. Options for HIV prevention and treatment continue to expand at a rapid pace.
Physician, Nursing and CMCN credits valid to December 31, 2018

Treatment of Chronic Hepatitis C Virus Infection

Hepatitis is the inflammation of the liver. There are several types of HCV, genotype 1A is the most prevalent in the US, and it’s been the most difficult to treat and cure. There are approximately 3.2 million people in the US with chronic Hepatitis C (CHC) infection. There could be many more, as HCV infections usually show mild to no symptoms. The most prevalent population believed to be infected with the hepatitis C virus (HCV) were born from 1945 to 1965 and probably infected during the 1970’s and ‘80’s, and many of them still are undiagnosed due to the lack of symptoms. Fortunately for patients with hepatitis C, several new treatment options have become available, giving physicians individualized options with vastly increased cure rates.

This program on overcoming challenges in HCV management with novel therapies will take a close look at genotype 1 and 4 HCV, providing attendees with education that will assist them in developing the best strategy to improve outcomes for their Hepatitis C member population. Attendees will leave with ability to increase screening protocols for Hepatitis C, and understand treatment barriers and solutions for patient adherence, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.
Physician, Nursing and CMCN credits valid to December 31, 2018

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, HemophiliaInfectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Musculoskeletal & Rheumatology

A 4-Part Series:  New Horizons in the Treatment and Management of Rheumatoid Arthritis

Description:  Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. With so many new options becoming available for clinicians, it is critical that rheumatologists, primary care physicians, managed care medical directors, payers, case managers, nurses, and other healthcare professionals (HCPs) are updated on these emerging options and guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits apply. Each session has its own specific valid dates.

Exploring Mechanisms of Action in JAK Inhibitors and the Role of the JAK/STAT Pathway in the Pathogenesis of RA

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019

Where Do JAK inhibitors Fit in the Emerging Treatment Paradigm in the Management of RA

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019

How to Improve Patient Adherence and Safety in RA: Strategies to Monitor and Manage Adverse Events Associated with Emerging JAK Inhibitors

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019

What Managed Care Needs to Know About JAK Inhibitors in the Evolving Management of RA

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body’s own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Neurological

Individualizing Therapy in the Management of Relapsing Multiple Sclerosis: Expert Strategies for Improved Patient Outcomes

Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults in the United States with a prevalence of approximately 400,000 cases. Multiple sclerosis may not be diagnosed for months to years after the onset of symptoms and some strategies for diagnosis include a careful medical history, a neurologic exam and various tests, including magnetic resonance imaging (MRI), evoked potentials (EP) and spinal fluid analysis. Although there is no cure for MS, many advances in treatment options have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Treatment is focused on disease-modifying agents, which helps lessen the frequency and severity of relapses, reduce lesions in the brain, and help slow or stop disability. Many therapeutic and technological advances are improving our understanding of the complex mechanisms involved in multiple sclerosis (MS) immunopathophysiology. Several investigational agents that have recently completed clinical trials that focus on Sphingosine-1-phosphate (S1P) signaling. S1P-based therapeutics in current clinical trials have shown improved efficacy, safety and deliverability.
Physician, Nursing and CMCN credits valid to August 1, 2019

Exploring Treatment Advances in Epilepsy: Keys to Optimizing Adherence and Patient Outcomes

Epilepsy is a chronic neurological disorder where the nerve cell activity in the brain becomes disrupted, causing seizures or periods of unusual behavior. Epilepsy affects about 3 million people in the United States and accounts for about $15 billion in medical costs. The diagnosis of epileptic seizures is made by analyzing the patient’s clinical history as well as performing neurophysiological and neuroimaging tests. Treatment of epilepsy involves reducing the number of seizures by administering various antiepileptic drugs (AEDs). This approach requires long-term adherence from patients. Uncontrolled seizures and their associated comorbidities, such as depression, can have detrimental effects on the patient’s quality of life. The development of new AEDs continues to increase and drug therapies can now be individualized to the patient’s symptoms and needs. It is also important to understand the mechanisms of action and the pharmacokinetics of antiepileptic drugs so that these agents can be used effectively in clinical practice, especially in the combined therapeutic strategies.
Physician, Nursing and CMCN credits valid to April 30, 2019

What’s New in the Management of Insomnia: Managed Care Considerations in an Evolving Treatment Landscape

The program will be on newer therapies in insomnia management, with a close look at the role of orexin receptor antagonists. The program will focus on elderly insomnia patients, which is a particular need among our membership. The activity will also touch on the management of middle aged women who suffer from insomnia. The program will discuss the importance of provider/patient communication, and how communication can be improved among all parties, including payers, to improve patient adherence & outcomes.
Physician, Nursing and CMCN credits valid to April 30, 2019

Best Practices in the Management of Relapsing Multiple Sclerosis: Advanced Strategies for Improved Patient Outcomes

Multiple Sclerosis (MS) is a chronic, progressive disease and is the most common neurological cause of disability among young adults. In many cases, MS may not be diagnosed for months to years after the onset of symptoms and current treatment is focused on disease-modifying agents to help lessen the frequency and severity of relapses, reduce lesions in the brain, and aid in slowing or stopping disability. With screening and diagnosing, it is critical that physicians note a detailed patient history and perform a complete physical and neurological exam. In addition, strategies for diagnosis include an MRI, evoked potentials (EP) and a spinal fluid analysis. Several factors must be considered when selecting a treatment regimen including variations in clinical and MRI evidence of disease. Thankfully many advances in diagnosis and treatment have arrived in recent years, allowing patients to better manage their symptoms, improve their quality of life, and increase mortality. The numerous revisions and advances in diagnostic criteria and multiple, new emerging therapies have shown new agents have the ability to improve outcomes in both safety and efficacy. Clinicians need to compare these new options with current therapies to form an individualized treatment strategy for each patient as symptoms are highly variable from person to person. Physician, Nursing and CMCN credits valid to April 30, 2019

New Horizons in the Management of Alzheimer’s Disease: Advances in Early Diagnosis & Treatment Strategies

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Currently, an autopsy or brain biopsy is the only way to make a definitive diagnosis of Alzheimer’s disease. In clinical practice, the diagnosis is typically made on the basis of the history and findings on Mental Status Examination. There is no single test that can show whether a person has Alzheimer’s. While physicians can almost always determine if a person has dementia, it may be difficult to determine the exact cause. Diagnosing Alzheimer’s requires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging.

The importance of early diagnosis cannot be understated. As the use of biomarkers continues to grow, the potential for catching Alzheimer’s disease even earlier is crucial to improving outcomes. Today, there is no treatment that can reverse the disease, and all the available treatments to Alzheimer’s are symptomatic therapies. The standard medical treatments include cholinesterase inhibitors, a partial N -methyl-D-aspartate (NMDA) antagonist and memantine, which helps with brain cell communication. However, advances in the science underlying Alzheimer’s are also emerging at a rapid rate, while a large number of potential agents are undergoing clinical trials. Many of these new therapies are based on an understanding of the pathogenesis of Alzheimer’s disease, and are designed to try to either slow or halt the progression of the disease. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area.
Physician, Nursing and CMCN credits valid to January 31, 2019

Clinical Insights into the Diagnosis & Treatment of Epilepsy

Epilepsy is a chronic neurological disorder that affects about 3 million people in the United States and accounts for about $15 billion in medical costs. Diagnosis of epilepsy is made by analyzing the patient’s clinical history as well as performing neurophysiological and neuroimaging tests. Treatment of epilepsy involves reducing the number of seizures by administering various antiepileptic drugs (AEDs), to include anticonvulsants, with the goal to achieve a seizure-free status. However long-term adherence is required from patients and unfortunately, more than one-third of patients continue to experience seizures or suffer from severe adverse effects. The development of new AEDs continues to increase and drug therapies can now be individualized to the patient’s symptoms and needs. It is also important to understand the mechanisms of action and the pharmacokinetics of antiepileptic drugs so that these agents can be used effectively in clinical practice, especially in the combined therapeutic strategies.
Physician, Nursing and CMCN credits valid to January 31, 2019

7-Part Series: New Horizons in the Treatment and Management of Multiple Sclerosis: Best Practices for Improved Patient Outcomes

New Horizons in the Treatment and Management of Multiple Sclerosis is a 7-part series that will provide participants with the latest information in MS management. By clicking on each of the titles, you will be able to participate in each part. It is not required that you participate in all 7 or in order. These are archives of live webinars held between December 7, 2016 and February 1, 2017.
Physician, Nursing and CMCN credits

Managing Relapse in MS: Strategies for Switching Therapy after Inadequate Response to Previous Treatment Regimens

Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. As part of a multi-part webinar program this session will focus on managing relapse and switching therapy. It is critical that HCPs who will be in attendance for the live webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.
Physician, Nursing and CMCN credits valid to January 31, 2019

Oral Therapies, Autoinjectors and Dosing/Administration in the Changing MS Management Paradigm: Overcoming Barriers to Treatment

Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2019

What’s on the Horizon in MS: A Review of Novel Therapies and Emerging Approaches

Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2019

Insights on the Interplay of B cells and T cells in Therapeutic MS Management

Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2019

What’s on the Horizon in MS: What Managed Care Needs to Know in the Evolving Management of MS

Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2018

New Horizons in the Treatment and Management of Multiple Sclerosis: The Role of Vitamin D in Multiple Sclerosis Pathology and Treatment

Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence. This session will provide attendees with the role and impact of vitamin D on clinical outcomes and neuroprotective mechanisms in MS.
Physician, Nursing and CMCN credits valid to March 31, 2018

New Horizons in the Treatment and Management of Multiple Sclerosis: Exploring Novel Mechanisms of Action in the Treatment of MS

Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. As part of a multi-part webinar program this session will focus on novel mechanisms of action. It is critical that HCPs who will be in attendance for the live webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.
Physician, Nursing and CMCN credits valid to December 31, 2018

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Pain Management

New Frontiers in the Treatment and Prevention of Migraines: A Closer Look at the Role of Emerging CGRP Targeted Therapies

Migraine is a major neurological disease that affects more than 36 million men, women and children in the United States. Migraine headache is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. In many patients with migraine headache, their pain is unrelieved, and recurrence of migraine is a common reason for patient dissatisfaction with treatment. The diagnosis of a migraine is based on signs and symptoms and neuroimaging tests are not necessary to diagnose migraine but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment however currently available migraine therapy is often inadequate. Fortunately for patients who suffer from migraine headaches, a new class of therapy is emerging that has shown to offer vastly improved efficacy and safety over traditional treatment regimens. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and look to offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines. CGRP monoclonal antibodies are specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache. The role of CGRP in migraine has been verified by basic research and several therapies are currently undergoing late stage clinical trials.
Physician, Nursing and CMCN credits valid to July 31, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophiliaInfectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Pulmonary

Clinical Advances in Idiopathic Pulmonary Fibrosis: New Treatment Goals and Strategies

Idiopathic pulmonary fibrosis (IPF) is a lung disease that results from the formation of scar tissue deep inside the lungs and is the most common of the idiopathic interstitial pneumonias. IPF is a devastating disease associated with irreversible destruction of the lung as the scarring gets progressively worse which makes it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. The condition is more common in men than in women, and its frequency increases with age between 40 and 70 years. IPF typically has a poor prognosis and the median survival rate is less than four years or fewer from diagnosis. Most patients with IPF present with a gradual onset, which makes it difficult to diagnosis early. Healthcare professionals are constantly looking at ways to diagnosis the disease much earlier to improve outcomes. It must start with the elicitation of a thorough and extensive medical history that should include review of symptoms or signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Patients may also complain of paroxysmal dry cough, shortness of breath, and fatigue. Despite a growing prevalence, patients with IPF continue to suffer delays in diagnosis which can limit treatment options, as well as increase costs, reduce patient quality of life, and impact survival.
Physician, Nursing and CMCN credits valid to August 1, 2019

Clinical Advances in the Diagnosis, Treatment and Management of COPD

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs and is the third-leading cause of death in the US, following cancer and heart disease. COPD is an incurable and progressive disease so early diagnosis is very important to decrease lung damage and reduce costs. Unfortunately, COPD is substantially under-diagnosed, undertreated, and is devalued as a major health issue. Smoking is the most common contributing cause of COPD in the US and if not treated early on and aggressively, can lead to disability, comorbid conditions, decreased quality of life, and an increased risk of premature death. Spirometry is required for the diagnosis of COPD. Treatment goals of COPD include relieving symptoms, improving health status and quality of life, reducing the number and severity of exacerbations, preventing and treating complications, and ensuring appropriate end-of-life planning and palliation. The recommended guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) share that all COPD patients should continuously be assessed based on their symptoms, the severity of airflow limitation, frequency of exacerbations, and comorbidities. The updated GOLD report further adds a thorough review of nonpharmacologic treatment options, in addition to receiving influenza and pneumococcal vaccinations to decrease the risk for lower respiratory tract infections.
Physician, Nursing and CMCN credits valid to August 1, 2019

Recent Advances in CFTR Modulator Therapy in the Management of Cystic Fibrosis: Best practices for Improved Patient Outcomes

Cystic fibrosis (CF) is a genetic, autosomal recessive disorder that affect the lungs, pancreas, liver, kidneys and intestine. Long-term issues include difficulty breathing and coughing up sputum, sinus infections, poor growth, fatty stool, clubbing of the finger and toes, and infertility in males. CF is caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR) which is involved in the production of sweat, digestive fluids, and mucus. The condition is diagnosed by a sweat test and genetic testing and screening of infants at birth takes place in some areas of the world. There is no cure for cystic fibrosis but fortunately a new treatment is available for those who have two copies of the F508del mutation in their CFTR gene (about half of patients). This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breath more easily and stay out of the hospital, providing a greater quality of life and improved outcomes.
Physician, Nursing and CMCN credits valid to August 8, 2019

Exploring the Challenges of Severe Asthma: Implementing Personalized Treatment Plans for Improved Patient Outcomes

Approximately 26 million Americans suffer from asthma with the prevalence of severe asthma being 10% of the asthmatic population. The goal of treatment strategies and controlling a patient’s asthma, preventing the symptoms, and minimizing adverse effects has shifted within the last few years. Today, there is more of an approach to implementing a personalized treatment plan as a key component to patient adherence and overall asthma control. One of these treatment plans includes using pharmacologic management through inhaled corticosteroids (ICS), long-acting beta-2 agonists, theophylline, and leukotriene modifiers. And while these are helping, several new therapies, such as anti-immunoglobulin E and anti-IL- antibodies, are aiming to control and treat asthma, which could improve the lives of patients with uncontrolled persistent asthma. More recent studies and clinical data show that new treatments such as biologics and injectables are set to become available and could help improve lung function, reduce severe exacerbations and decrease rescue bronchodilator use. Patient adherence also plays a key role in satisfaction with a personalized treatment plan. Clinicians can improve patients’ inhaler technique by assessing for and correcting inhaler errors on a regular basis; however, evidence suggests that many clinicians do not perform this guideline-recommended assessment. These new options will also reduce the number of hospital visits and ultimately reduce cost. Patient nonadherence and poor inhaler technique have been linked to higher rates of uncontrolled asthma, with concomitant increases in disease burden and healthcare utilization. With all the recent advances in therapeutic options it is being shown a personalized treatment plan needs to be put in the management strategy.
Physician, Nursing and CMCN credits valid to August 3, 2019

The Future Management of IPF: Advanced Diagnostic & Treatment Strategies

Idiopathic pulmonary fibrosis (IPF) is a devastating disease associated with irreversible destruction of the lung(s) which progressively worsens, making it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. The condition frequency increases with age, is more common in men than in women, and has a median survival rate of 4 years or less from the time of diagnosis. IPF is the most common of the idiopathic interstitial pneumonias and typically has a poor prognosis as the disease exhibits a gradual onset, making it difficult to diagnosis early. Earlier diagnosis begins with elicitation of a thorough and extensive medical history that includes a review of symptoms/signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Despite a growing prevalence, patients with IPF continue to suffer delays in diagnosis, increased costs, and a reduction in patient quality of life and overall survival.

Treatment strategies for IPF aim at managing the symptoms and slowing disease progression to best maintain a patient’s quality of life. The therapeutic landscape is rapidly evolving and current and emerging therapies are shown to slow disease progression which ultimately brings about a need for earlier diagnosis and intervention in IPF. More recently, therapeutic options for IPF have evolved to include targeted agents that have the ability to individualize treatment for patients. The standard of care for IPF includes oxygen supplementation, management of co-morbidities, lung transplants, and implementing nintedanib and pirfenidone, according to updated guidelines.
Physician, Nursing and CMCN credits valid to February 28, 2019

Clinical Updates in Cystic Fibrosis: Applying Recent Advances in CFTR Modulator Therapy for Improved Patient Outcomes

Cystic fibrosis (CF) is a genetic, autosomal recessive disorder caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). Cystic Fibrosis mostly affects mostly the lungs but also the pancreas, liver, kidneys and intestine. Common symptoms include difficulty breathing, sinus infections, poor growth, fatty stool, clubbing of the finger and toes, and infertility in males among others. There is no cure for cystic fibrosis, but recent treatment breakthroughs are available for about half of CF patients who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breath more easily and stay out of the hospital, improving outcomes and quality of life. This option is a major breakthrough in CF management, because it is the first therapy that specifically targets an important genetic mutation.
Physician, Nursing and CMCN credits valid to January 31, 2019

Optimizing Mild to Moderate Asthma Management: A Clinician’s Toolkit for Adherence and Technology

The goal of the Spotlight video roundtable activity is to improve knowledge and competence among medical directors and nurses from employers, health plans and provider systems and other managed care HCPs, including allergists/clinical immunologists, pulmonologists, primary care physicians (PCPs), and pharmacists, related to the optimal selection of inhaled therapy devices, improvement of patient inhaler technique, and encouragement of patient adherence with inhaled therapies for mild to moderate asthma. The educational initiative is designed to induce changes in clinician awareness, knowledge, and clinical skills that can contribute to improved quality of patient care. The discussion will examine inhaler technology and formulations and how they relate to adherence and allow faculty to analyze and present key information on the evidence-based management of mild-to-moderate asthma while highlighting practical strategies for patient care.
Physician, Nursing and CMCN credits valid to January 31, 2019

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  DiabetesHemophilia, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Pain Management,  Pulmonary, Urology

Urology

Payer Challenges & Issues in the Management of OAB: Improving Patient Outcomes with Optimal Cost & Treatment Strategies

Overactive bladder (OAB) is a highly prevalent condition that occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more predominant with advanced age. OAB has a significant impact on quality of life (QoL), co-morbidities and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. Despite its impact, OAB remains underdiagnosed and undertreated. Screening and evaluating patients is of utmost importance in order to improve diagnosis and patient QoL. Once diagnosed, a stepwise progression is recommended to manage the disease. Multiple options of treatment are available, providing a tailored approach to individualize treatment based upon a patient’s expectation and goal for treatment, their co-morbidities, symptoms, and the side-effects of treatments. What works and does not work will vary patient to patient and it’s important to keep communications open to determine if a patient is unable to remain compliant to treatment due to side-effects or cost.
Physician, Nursing and CMCN credits valid to April 30, 2019

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.
Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.